BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and Its Management. Nutr Clin Pract 2020;35:72-84. [PMID: 31840865 DOI: 10.1002/ncp.10449] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Du C, Shen L, Ma Z, Du J, Jin S. Bioinformatic Analysis of Crosstalk Between circRNA, miRNA, and Target Gene Network in NAFLD. Front Genet 2021;12:671523. [PMID: 33995497 DOI: 10.3389/fgene.2021.671523] [Reference Citation Analysis]
2 Lee DU, Fan GH, Hastie DJ, Addonizio EA, Prakasam VN, Ahern RR, Suh J, Seog KJ, Karagozian R. The clinical impact of cirrhosis on the postoperative outcomes of patients undergoing bariatric surgery: propensity score-matched analysis of 2011-2017 US hospitals. Expert Rev Gastroenterol Hepatol 2021;:1-10. [PMID: 33706616 DOI: 10.1080/17474124.2021.1902803] [Reference Citation Analysis]
3 Rice J, Ramtekkar U. Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics. Med Sci (Basel) 2020;8:E34. [PMID: 32824428 DOI: 10.3390/medsci8030034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Dallio M, Romeo M, Gravina AG, Masarone M, Larussa T, Abenavoli L, Persico M, Loguercio C, Federico A. Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives. Nutrients 2021;13:1679. [PMID: 34063372 DOI: 10.3390/nu13051679] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Zhang W, Li H, Zhao N, Luo X, Liu S, Bao A, Chen Y, Wang H, Wang J, Wang J. Lactobacillus johnsonii BS15 combined with abdominal massage on intestinal permeability in rats with nonalcoholic fatty liver and cell biofilm repair. Bioengineered 2021;12:6354-63. [PMID: 34511035 DOI: 10.1080/21655979.2021.1954134] [Reference Citation Analysis]
6 Zhang JL, Du BB, Zhang DH, Li H, Kong LY, Fan GJ, Li YP, Li PC, Liang C, Wang Z, Yang LL, Hao ZY, Wu LM, Huang Z, Dong JZ, Zhang JY, Yao R, Wang SJ, Zhang YZ. OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways. Hepatology 2021. [PMID: 34591986 DOI: 10.1002/hep.32179] [Reference Citation Analysis]
7 Zhang S, Zhao J, Xie F, He H, Johnston LJ, Dai X, Wu C, Ma X. Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease. Obes Rev 2021;:e13316. [PMID: 34279051 DOI: 10.1111/obr.13316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Petermann-rocha F, Gray SR, Forrest E, Welsh P, Sattar N, Celis-morales C, Ho FK, Pell JP. Associations of muscle mass and grip strength with severe NAFLD: a prospective study of 333,295 UK Biobank participants. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.010] [Reference Citation Analysis]
9 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Reference Citation Analysis]
10 Errafii K, Al-Akl NS, Khalifa O, Arredouani A. Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4. J Transl Med 2021;19:235. [PMID: 34078383 DOI: 10.1186/s12967-021-02885-4] [Reference Citation Analysis]
11 Song C, Lv W, Li Y, Nie P, Lu J, Geng Y, Heng Z, Song L. Alleviating the effect of quinoa and the underlying mechanism on hepatic steatosis in high-fat diet-fed rats. Nutr Metab (Lond) 2021;18:106. [PMID: 34922572 DOI: 10.1186/s12986-021-00631-7] [Reference Citation Analysis]
12 do Moinho TM, Matos SL, Carvalho CRO. A comprehensive review on phytochemicals for fatty liver: are they potential adjuvants? J Mol Med (Berl) 2022. [PMID: 34993581 DOI: 10.1007/s00109-021-02170-3] [Reference Citation Analysis]
13 Jarmakiewicz-czaja S, Sokal A, Pardak P, Filip R, Granito A. Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-13. [DOI: 10.1155/2022/4344905] [Reference Citation Analysis]
14 Li X, Zhao W, Xiao M, Yu L, Chen Q, Hu X, Zhao Y, Xiong L, Chen X, Wang X, Ba Y, Guo Q, Wu X. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice. J Ethnopharmacol 2022;:115333. [PMID: 35500802 DOI: 10.1016/j.jep.2022.115333] [Reference Citation Analysis]
15 Alrashood ST, Al-Asmari AK, Alotaibi AK, Manthiri RA, Rafatullah S, Hasanato RM, Khan HA, Ibrahim KE, Wali AF. Protective effect of lyophilized sapodilla (Manilkara zapota) fruit extract against CCl4-induced liver damage in rats. Saudi J Biol Sci 2020;27:2373-9. [PMID: 32884419 DOI: 10.1016/j.sjbs.2020.05.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Jiang T, Guo XJ, Tu LP, Lu Z, Cui J, Ma XX, Hu XJ, Yao XH, Cui LT, Li YZ, Huang JB, Xu JT. Application of computer tongue image analysis technology in the diagnosis of NAFLD. Comput Biol Med 2021;135:104622. [PMID: 34242868 DOI: 10.1016/j.compbiomed.2021.104622] [Reference Citation Analysis]
17 Garcia-Martinez I, Alen R, Rada P, Valverde AM. Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis. Front Med (Lausanne) 2020;7:395. [PMID: 32850903 DOI: 10.3389/fmed.2020.00395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yang H, Zhang T, Rayamajhi S, Thapa A, Du W, Meng G, Zhang Q, Liu L, Wu H, Gu Y, Zhang S, Wang X, Li H, Zhang J, Dong J, Zheng X, Cao Z, Zhang X, Dong X, Sun S, Wang X, Zhou M, Jia Q, Song K, Niu K. The longitudinal associations between sweet potato intake and the risk of non-alcoholic fatty liver disease: the TCLSIH cohort study. International Journal of Food Sciences and Nutrition. [DOI: 10.1080/09637486.2022.2050997] [Reference Citation Analysis]
19 Jiménez-Cortegana C, García-Galey A, Tami M, Del Pino P, Carmona I, López S, Alba G, Sánchez-Margalet V. Role of Leptin in Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:762. [PMID: 34209386 DOI: 10.3390/biomedicines9070762] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Toor R, Chana I. Exploring diet associations with Covid-19 and other diseases: a Network Analysis-based approach. Med Biol Eng Comput 2022. [PMID: 35171411 DOI: 10.1007/s11517-022-02505-3] [Reference Citation Analysis]
21 Dubey SR, Ashavaid TF, Abraham P, Paradkar MU. Factors influencing circulating microRNAs as biomarkers for liver diseases. Mol Biol Rep. [DOI: 10.1007/s11033-022-07170-1] [Reference Citation Analysis]
22 Videla LA, Valenzuela R. Perspectives in liver redox imbalance: Toxicological and pharmacological aspects underlying iron overloading, nonalcoholic fatty liver disease, and thyroid hormone action. Biofactors 2021. [PMID: 34687092 DOI: 10.1002/biof.1797] [Reference Citation Analysis]
23 Ali Z, Saeed IM, Bybee KA, Thompson R, O'Keefe JH, Shafiq M, Saeed L, Zafar Y, Kennedy KF, Al-Sayyed L. Correlation of Hepatic Steatosis Among Cohabitants Using Hounsfield Unit From Coronary Computed Tomography. Cureus 2021;13:e17834. [PMID: 34660042 DOI: 10.7759/cureus.17834] [Reference Citation Analysis]
24 Kwon HC, Sohn H, Kim DH, Jeong CH, Kim DW, Han SG. Effects of Flutriafol Fungicide on the Lipid Accumulation in Human Liver Cells and Rat Liver. Foods 2021;10:1346. [PMID: 34200939 DOI: 10.3390/foods10061346] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Policarpo S, Machado MV, Cortez-Pinto H. Telemedicine as a tool for dietary intervention in NAFLD-HIV patients during the COVID-19 lockdown: A randomized controlled trial. Clin Nutr ESPEN 2021;43:329-34. [PMID: 34024536 DOI: 10.1016/j.clnesp.2021.03.031] [Reference Citation Analysis]
26 Luo Y, Zhang Z, Xiang L, Zhou B, Wang X, Lin Y, Ding X, Liu F, Lu Y, Peng Y. Analysis of N6-Methyladenosine Methylation Modification in Fructose-Induced Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:780617. [PMID: 34950107 DOI: 10.3389/fendo.2021.780617] [Reference Citation Analysis]
27 Darbà J. Direct medical costs of non-alcoholic fatty liver disease in Catalonia at the hospital level: a retrospective multicenter study. Expert Rev Pharmacoecon Outcomes Res 2021;:1-9. [PMID: 33593235 DOI: 10.1080/14737167.2021.1890586] [Reference Citation Analysis]
28 Ezhilarasan D, Lakshmi T, Kosuru R. A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. Oxidative Medicine and Cellular Longevity 2022;2022:1-15. [DOI: 10.1155/2022/9233650] [Reference Citation Analysis]
29 Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, Foltran L, Ongaro E, Puglisi F. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. Cells 2021;10:2034. [PMID: 34440803 DOI: 10.3390/cells10082034] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Perez-Diaz-Del-Campo N, Riezu-Boj JI, Marin-Alejandre BA, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Milagro FI, Tur JA, Abete I, Zulet MA, Martinez JA. Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study. Diagnostics (Basel) 2021;11:1083. [PMID: 34199237 DOI: 10.3390/diagnostics11061083] [Reference Citation Analysis]
31 Gao G, Xie Z, Li EW, Yuan Y, Fu Y, Wang P, Zhang X, Qiao Y, Xu J, Hölscher C, Wang H, Zhang Z. Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis. J Nat Med 2021;75:540-52. [PMID: 33590347 DOI: 10.1007/s11418-021-01491-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]